ASX healthcare stocks divide sharply as deals meet clinical setbacks
Mayne Pharma delivered the week’s biggest gain after accepting a A$604 million takeover, while Actinogen and Argenica suffered heavy losses on clinical and regulatory setbacks.
Healthcare earnings also split sharply, with IDT forecasting a return to profit as Monash IVF warned of a weaker year.
- Mayne Pharma accepted a A$6.40-a-share cash offer from Gedeon Richter, valuing its equity at about A$604 million.
- Actinogen shares fell 80% while trading was suspended ahead of Alzheimer’s trial results.
- Argenica dropped 41.67% after the US FDA kept its stroke drug on clinical hold.
- IDT rose 35.29% after forecasting FY27 revenue of A$19 million to A$20 million and positive EBITDA.
- Monash IVF withdrew its FY27 earnings guidance after weaker Australian IVF volumes and higher costs.
Add us as a preferred source on Google
The week’s three biggest share moves came from very different events. Mayne Pharma (ASX:MYX) rose 83.03% after agreeing to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter. Actinogen Medical (ASX:ACW) fell 80.00% while suspended before Alzheimer’s trial results. Argenica Therapeutics (ASX:AGN) dropped 41.67% after the US Food and Drug Administration kept its stroke drug on clinical hold.
Clinical news drove the largest falls
Actinogen halted trading after receiving more data from its 247-patient XanaMIA trial. The study is testing whether Xanamem can slow decline in people with Alzheimer’s disease. Investors were left waiting for the main result. The shares later reopened at A$0.006 and moved 50% higher from that level, showing that early losses were partly recovered.
Argenica faced a clearer setback. The FDA wants a new safety study in rats before it will consider lifting the hold on xaranetide, its stroke treatment. The agency also set a lower exposure limit than the company wanted for its next trial. The shares fell a further 36.36% after reopening at A$0.11. That continued selling shows investors remain worried about delay, safety and the amount of work still needed.
Earnings produced a mixed picture
IDT Australia (ASX:IDT) rose 35.29% after forecasting its first positive EBITDA, a measure of profit before interest, tax and some non-cash costs. It expects FY27 revenue of A$19 million to A$20 million and EBITDA of A$1 million to A$1.5 million. Larger contracts, a five-year radiopharmaceutical agreement and about A$7 million of factory upgrades support the forecast. The risk is that the new contracts and upgrades take longer to produce cash.
Monash IVF Group (ASX:MVF) moved the other way, falling 23.33%. The company now expects FY27 net profit after tax to sit well below both FY26 and earlier analyst estimates. Australian stimulated IVF cycles fell 3.2% in the first quarter. Higher depreciation, interest and capacity costs added to the pressure. A delayed A$8 million to A$11 million productivity programme gives investors less confidence in a quick recovery.
Resonance Health (ASX:RHT) reported a A$1.5 million profit after revenue rose 42% to A$15.8 million, but its shares fell 13.04%. One large MASH trial supplied 48% of last year’s revenue and is due to finish in early 2027. Investors must now judge whether new obesity, fibrosis and clinical-trial services can replace that work.
Deals and commercial progress
Mayne Pharma’s proposed takeover carries a 99.4% premium to its 16 November closing price. Shareholders representing 22.14% of the company have backed the board’s recommendation. The deal still needs shareholder and court approval, regulatory clearances and completion of Mayne’s international business sale. Implementation is targeted for mid to late March 2027, so the cash payment is not yet certain.
Genetic Signatures (ASX:GSS) abandoned its proposed merger with Microba Life Sciences after Microba said it needed more capital to complete the deal. GSS declined to provide unsecured working capital funding. The stock fell 2.78% for the week and moved 9.09% lower after reopening at A$0.077. BCAL Diagnostics (ASX:BDX) had offered conditional support for a revised transaction, but those proposed terms no longer guarantee that a merger will proceed.
Partnership news offered smaller companies a way to expand, but most agreements still require proof of sales. Xenitra (ASX:XEN) secured a three-year, non-binding A$100 million sales target with JD Health and rose 16.67%. The first-year target is A$14 million, with sales intended to start in January 2027. EBR Systems (ASX:EBR) gained 3.23% after US officials proposed national Medicare coverage for its WiSE heart-pacing system. The proposal still needs public comment and a final decision by 16 February 2027.
Elsewhere, EMVision Medical Devices (ASX:EMV) secured a A$3 million grant to test its scanner for brain injury, while ReNerve (ASX:RNV) completed its first commercial NervAlign procedure in India. ReNerve’s shares still fell 15.66% for the week and remained 12.5% below the reopening price. The clinical and sales milestones must now translate into repeat procedures and revenue.
Cash and costs remain central
Regis Healthcare (ASX:REG) lifted FY26 revenue 16% to A$1.35 billion and held A$173.8 million of net cash, but its shares fell 9.94%. Management says government funding rose 2.55%, below the growth in its costs. Regis is cutting support-office costs and seeking price increases. Full annual savings are expected in FY28, leaving investors to wait for the benefit.
ParagonCare (ASX:PGC) rose 6.67% after underlying EBITDA increased 16.5% to A$97.2 million, despite a bad-debt charge linked to Infinity Pharmacy Group. The company completed six acquisitions and is running a daily share buyback. It paid no FY26 dividend, so investors will want to see whether debt and cash improve alongside earnings.
Neurizon (ASX:NUZ) opened a A$2 million share purchase plan to fund its ALS programme towards a late second-quarter 2027 result. The offer includes a possible free option for each new share, subject to shareholder approval and ASX quotation. Cann Group (ASX:CAN) also reported stronger exports and lower costs, but its normalised FY26 loss remained A$14.7 million. Improving sales have not yet produced steady profits.
This Week's Sector Wraps
Compare performance across the market
Bottom Line?
The next major tests arrive through the planned XanaMIA results, the FDA’s further review of Argenica’s xaranetide programme and the final Medicare decision on EBR’s WiSE system. Mayne Pharma’s takeover is targeted for completion in mid to late March 2027, while Neurizon is working towards a late second-quarter 2027 ALS readout. Investors will also watch whether IDT can deliver its FY27 profit forecast and whether Monash IVF can restore growth after its guidance withdrawal.
Questions in the middle?
- Will Actinogen’s XanaMIA results support a return to trading value after the suspension?
- Can Argenica satisfy the FDA’s new safety requirements without a long delay or another capital raise?
- Will IDT’s larger contracts and factory upgrades deliver positive cash flow, while Monash IVF stabilises IVF volumes and costs?
Sources
17This wrap draws on announcements from 17 companies. For the full story and each verified source, see the company's own article:
ASX:1AD, ASX:ACW, ASX:AGN, ASX:BDX, ASX:CAN, ASX:EBR, ASX:EMV, ASX:GSS, ASX:IDT, ASX:MVF, ASX:MYX, ASX:NUZ, ASX:PGC, ASX:REG, ASX:RHT, ASX:RNV, ASX:XEN